Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Red Cell Survival in Sickle Cell Disease and Hemoglobinopathies Using Biotin Labeling
NCT06313398Phase 1Recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- May 2024
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Biotinylated red blood cell in sickle cell disease (SCD), thalassemia and hemoglobinopathy, sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Red Blood Cell Survival at 20 weeks. Started May 2024; status: recruiting.
02
Drugs
Biotinylated red blood cell
03
Conditions
sickle cell disease (SCD)thalassemiahemoglobinopathy
Beyond the preview
Go deeper on NCT06313398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06313398.